Mirvetuximab Soravtansine

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Mirvetuximab Soravtansine
   1. Pharmacist Assessment Report
   2. Mirvetuximab Soravtansine: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Mirvetuximab Soravtansine: Known uses and market status in Canada

Summary

The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Mirvetuximab Soravtansine, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	3
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
fallopian tube neoplasms	licence in another country
ovarian neoplasms	licence in another country
peritoneal neoplasms	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02560771	ELAHERE		Valid

Cytotoxicity

Item	Content
Cytotoxicity Classification	Antibody-drug conjugate with a cytotoxic payload (DM4, a maytansinoid microtubule inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert; ocular (corneal) examinations are relevant given the known ocular toxicity
Handling Protection	Follow institutional cytotoxic drug handling regulations

Safety Considerations

• Known toxicity: Drug-induced ocular (corneal) toxicity has been reported. It can be resolved with short-term topical steroids.
• Drug Interactions: The interaction query found only the drug’s pharmacological target, folate receptor alpha (FOLR1). No specific interacting drugs were identified.

For other safety information, please refer to the package insert.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---